Analyst Viewpoint
Rise in prevalence of T-cell acute lymphoblastic leukemia worldwide is a key factor boosting the T-cell acute lymphoblastic leukemia market size.
T-cell acute lymphoblastic leukemia is one of the aggressive types of blood cancer, wherein an excessive number of T-cell lymphoblasts (immature white blood cells) are found in blood and bone marrow.
Chemotherapy is the primary course of treatment for the disease.
Companies operating in the global T-cell acute lymphoblastic leukemia market are exploring supplementation of intensive chemotherapy with cranial radiotherapy (CRT).
They are also experimenting with hematopoietic stem cell transplantation. Autophagy is being targeted as pediatric ALL treatment.
In line with the latest T-cell acute lymphoblastic leukemia industry trends, key players are investigating novel immunotherapeutic strategies based on mAbs and chimeric antigen receptor (CAR)-T cells to increase cure rates and reduce the burden of intensive and prolonged maintenance chemotherapy.
T-cell acute lymphoblastic leukemia (T-ALL), also known as T-cell immunophenotype, is one of the uncommon types of leukemia that can present with lymphomatous and/or leukemic manifestations.
The immature white blood cells start accumulating in bone marrow and drive away white blood cells (healthy as well as unhealthy). The cells are also observed to build up in liver, lymph nodes, and spleen.
Symptoms of T-cell acute lymphoblastic leukemia include anemia, fatigue, weakness, shortness of breath, lightheadedness, heart palpitations, frequent infections, fever, sweats, bruising, and bleeding.
In advanced stages, the affected individual is likely to develop swollen lymph nodes in the center portion of the chest, thereby adversely affecting respiration.
As per the American Society of Clinical Oncology (ASCO), T-cell acute lymphoblastic leukemia accounts for 15% to 20% of all acute lymphoblastic leukemia.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
T-cell acute lymphoblastic leukemia is not a commonly known cancer. Majority of the cases of this cancer are found in children. T-cell Acute Lymphoblastic Leukemia attacks the immune system. Therefore, it is likely to lead to various other ailments such as pneumonia, cough, and high fever.
Those contracting T-cell acute lymphoblastic leukemia witness change in their chromosomes and genes, which may or may not get passed on to the progeny. Research states that close to 80% of the patients suffering from T-ALL witness deletion of the CDKN2A gene.
T-cell acute lymphoblastic leukemia occurs more due to mutations than external factors; however, research states that individuals exposed to carcinogenic chemicals such as benzene are at a higher risk of contracting T-cell acute lymphoblastic leukemia.
As per the International Energy Agency (IEA), the U.S. alone accounts for 40% of production of petrochemicals. Extensive T-cell acute lymphoblastic leukemia market research is being conducted across the globe to come up with innovative cell and gene treatments.
Novartis has developed the first CAR-T cell therapy approved for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). CAR-T cell therapy enhances the strength of a patient’s existing T cells to target B-cell malignancies.
Increase in research and development activities to introduce drugs and therapies for T-cell acute lymphoblastic leukemia therapeutics is fueling market progress.
As per an article titled ‘Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial’, CD7 CAR T cells from the donors who received single infusion of anti-CD7 CAR T cells achieved higher complete remission rate with passable safety profile. This trial was performed on 20 patients with refractory or relapsed T-cell acute lymphoblastic leukemia (r/r T-ALL).
According to an article titled ‘Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia’, adding nelarabine to the augmented Berlin-Frankfurt-Muenster (ABFM) therapy increased the percentage of disease-free survival (DFS) without increasing toxicity in young adults and children that were newly diagnosed with T-cell acute lymphoblastic leukemia.
Thus, advancements in medications, which are an outcome of speedy and successful clinical trials, is boosting T-cell acute lymphoblastic leukemia market dynamics.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest T-cell acute lymphoblastic leukemia market scenario, North America accounted for the largest share of the global landscape in 2022. The region is projected to maintain its dominance during the forecast period.
Growth in healthcare spending, especially by the U.S. Government, is fostering market expansion in North America. According to the Centers for Medicare and Medicaid Services, national health spending is estimated to witness a CAGR of 5.4% between 2019 and 2028 and reach US$ 6.2 Trn by 2028.
Presence of a strong healthcare infrastructure, robust product pipeline, and rapid advancements and innovations in treatment therapies are driving the T-cell acute lymphoblastic leukemia market share of North America.
Europe and Asia Pacific are likely to record considerable market growth in the near future owing to the rise in awareness about the importance of early diagnosis of T-cell acute lymphoblastic leukemia in these regions.
Companies operating in the global T-cell acute lymphoblastic leukemia industry are engaging in extensive research activities regarding combination of existing methods of treatment with the newly developed drugs.
They are working on combining targeted therapies with radiotherapy and immunotherapies for pediatric population suffering from T-cell acute lymphoblastic leukemia.
Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Erytech Pharma Inc., and Celgene Corporation are the key players covered in the research report on T-cell acute lymphoblastic leukemia market.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 241.9 Mn |
| Market Forecast (Value) in 2031 | US$ 450.9 Mn |
| Growth Rate (CAGR) | 7.5% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 241.9 Mn in 2022
It is projected to grow at a CAGR of 7.5% from 2023 to 2031
Rise in prevalence of T-cell acute lymphoblastic leukemia and advancements in medications
The chemotherapy segment accounted for the largest share in 2022
North America was the dominant region in 2022
Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Erytech Pharma Inc., and Celgene Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global T-cell Acute Lymphoblastic Leukemia Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2017-2031
6.3.1. Chemotherapy
6.3.2. Radiation Therapy
6.3.3. Bone Marrow Transplant
6.3.4. Targeted Therapy
6.3.5. Immunotherapy
6.4. Market Attractiveness Analysis, by Treatment
7. Global T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2017-2031
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment, 2017-2031
9.3.1. Chemotherapy
9.3.2. Radiation Therapy
9.3.3. Bone Marrow Transplant
9.3.4. Targeted Therapy
9.3.5. Immunotherapy
9.4. Market Value Forecast, by End-user, 2017-2031
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Market Value Forecast, by Country, 2017-2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By End-user
9.6.3. By Country
10. Europe T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment, 2017-2031
10.3.1. Chemotherapy
10.3.2. Radiation Therapy
10.3.3. Bone Marrow Transplant
10.3.4. Targeted Therapy
10.3.5. Immunotherapy
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment, 2017-2031
11.3.1. Chemotherapy
11.3.2. Radiation Therapy
11.3.3. Bone Marrow Transplant
11.3.4. Targeted Therapy
11.3.5. Immunotherapy
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment, 2017-2031
12.3.1. Chemotherapy
12.3.2. Radiation Therapy
12.3.3. Bone Marrow Transplant
12.3.4. Targeted Therapy
12.3.5. Immunotherapy
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment, 2017-2031
13.3.1. Chemotherapy
13.3.2. Radiation Therapy
13.3.3. Bone Marrow Transplant
13.3.4. Targeted Therapy
13.3.5. Immunotherapy
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. F. Hoffmann-La Roche Ltd.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Sanofi
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Erytech Pharma Inc.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Celgene Corporation
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
List of Tables
Table 01: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 02: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 03: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 04: North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 05: North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 06: North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 07: Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 08: Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 09: Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 10: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 11: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 12: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 13: Latin America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Latin America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 15: Latin America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 18: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
Figure 02: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn), by Treatment, 2022
Figure 03: Global T-cell Acute Lymphoblastic Leukemia Market Value Share, by Treatment, 2022
Figure 04: Global T-cell Acute Lymphoblastic Leukemia Market Revenue (US$ Mn), by End-user, 2022
Figure 05: Global T-cell Acute Lymphoblastic Leukemia Market Value Share, by End-user, 2022
Figure 06: Global T-cell Acute Lymphoblastic Leukemia Market Value Share, by Region, 2022
Figure 07: Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2023-2031
Figure 08: Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2022-2031
Figure 09: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 10: Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2022-2031
Figure 11: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031
Figure 12: Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2022-2031
Figure 13: Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2022-2031
Figure 14: North America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 15: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2023-2031
Figure 16: North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2022-2031
Figure 17: North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2022-2031
Figure 18: North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2022-2031
Figure 19: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 20: North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2023-2031
Figure 21: Europe T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 22: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 23: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 24: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2022-2031
Figure 25: Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2022-2031
Figure 26: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 27: Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2023-2031
Figure 28: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 29: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 30: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 31: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2022-2031
Figure 32: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2022-2031
Figure 33: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 34: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2023-2031
Figure 35: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 36: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 37: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 38: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2022-2031
Figure 39: Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2022-2031
Figure 40: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 41: Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2023-2031
Figure 42: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 43: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 44: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 45: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2022-2031
Figure 46: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2022-2031
Figure 47: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 48: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
T-cell Acute Lymphoblastic Leukemia Market
